表紙
市場調査レポート

市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症 - パイプライン製品の分析

Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015

発行 Global Markets Direct 商品コード 321923
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症 - パイプライン製品の分析 Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015
出版日: 2015年04月15日 ページ情報: 英文 36 Pages
概要

過去1年の間に入院や医療的な処置(透析、手術、カテーテルなど)を受けていないにもかかわらず、MRSAに感染した場合は市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症とされます。素因は血液透析、免疫システムの衰え、入院、外傷などです。皮膚の腫れ、疲労感、胸痛、熱、浮腫などが症状として挙げられます。

当レポートでは、市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

市中感染型メシチリン耐性黄色ブドウ球菌(MRSA)感染症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Achaogen Inc.
  • Furiex Pharmaceuticals, Inc.
  • Galapagos NV
  • Novan, Inc.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • acorafloxacin
  • GLPG-1492
  • NVN-4428
  • SB-204
  • Small Molecules to Inhibit Beta Lactamase for Bacterial Infections
  • Synthetic Peptide for Multi-Drug Resistant Bacterial Infections

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6651IDB

Summary

Global Markets Direct's, 'Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015', provides an overview of the Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview
    • Pipeline Products for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development
    • Furiex Pharmaceuticals, Inc.
    • Galapagos NV
    • Novan, Inc.
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acorafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1492 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVN-1000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVN-4428 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Multi-Drug Resistant Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Recent Pipeline Updates
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H1 2015
  • Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Furiex Pharmaceuticals, Inc., H1 2015
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Galapagos NV, H1 2015
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Novan, Inc., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Recent Pipeline Updates, H1 2015
  • Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects, H1 2015

List of Figures

  • Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H1 2015
  • Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top